Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial [0.03%]
一种偏向型环磷酸腺苷作用的胰高血糖素样肽-1受体激动剂艾思赞与度拉唐塞在单用二甲双胍血糖控制不佳的2型糖尿病患者中的疗效和安全性：一项52周、多中心、开放标签、非劣效性、随机三期临床试验（EECOH-2研究）
Yang He,Nianrong Mi,Zhifeng Cheng et al.
Yang He et al.
Background: Ecnoglutide is a novel biased GLP-1 receptor agonist that preferentially activates the cAMP pathway over β-arrestin recruitment. We aimed to assess both non-inferiority and superiority of ecnoglutide versus d...
Growing evidence for semaglutide efficacy in Asian adults with obesity [0.03%]
司美格鲁肽在肥胖亚洲成人中的疗效证据日益增多
Priya Sumithran,Louise A Baur
Priya Sumithran
Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial [0.03%]
东亚BMI≥25kg/m²成人肥胖症患者中每周一次司美格鲁肽2·4mg的疗效（III期STEP 11试验）：一项随机、双盲、安慰剂对照试验
Soo Lim,Supawan Buranapin,Xiaolei Bao et al.
Soo Lim et al.
Background: Consistent with WHO recommendations, obesity is defined as BMI ≥25 kg/m2 in many Asian populations because of increased health risks at lower BMIs than in other populations. We aimed to investigate the effica...
Susan Rahimi,Marta Koch
Susan Rahimi
Terry J Smith
Terry J Smith
Jennifer Lynn Sherr,Laura M Nally
Jennifer Lynn Sherr